Addiction-treatment - Articles - Page 3

Perioperative Management of Patients on Buprenorphine Maintenance

November 22, 2019

Gregory Acampora, MD

Psychiatrist, Pain Management Center, Massachusetts General Hospital/Harvard Center for Addiction Medicine, Boston, MA. Assistant Professor, Harvard Medical School.

Dr. Acampora has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

For patients on buprenorphine maintenance facing surgery, it is crucial to balance the need to minimize pain while addressing the risk of relapse. In this interview, Dr. Gregory Acampora guides us through the specifics on perioperatively managing patients on varying doses of buprenorphine maintenance.

Exposure Therapy Efficacious for PTSD Co-Occurring With Alcohol Use Disorder

November 22, 2019

Brian Frankel, MD

Brian Frankel, MD Dr. Frankel has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Prolonged exposure is one of the best treatments available for patients with PTSD. This study examines the advantages of using prolonged exposure for patients who have PTSD with co-occurring alcohol use disorder.

Varenicline and Bupropion: Soaring Again With EAGLES?

November 22, 2019

Nicholas Rosenlicht, MD.

Nicholas Rosenlicht, MD. Dr. Rosenlicht has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This research update unpacks the details behind the landmark “EAGLES” trial (Evaluating Adverse Events in a Global Smoking Cessation Study), which led to the removal of the varenicline black box warning.

The COMBINE Study: A Core Paper in the Treatment of AUD

November 22, 2019

Brian Frankel, MD

Brian Frankel, MD Dr. Frankel has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This research update summarizes the results of the landmark COMBINE study which evaluated the effectiveness of stand-alone and combined pharmacological and behavioral interventions for treating alcohol use disorder.

Primer: Evidence-Based Psychosocial Interventions for Substance Use Disorders

October 2, 2019

Psychosocial interventions for substance use disorders include drug counseling, medical management, cognitive behavioral therapy, motivational interviewing, contingency management, the community reinforcement approach, and twelve-step facilitation

Treating Alcohol Use Disorder

October 2, 2019

Albert J. Arias, MD, MS

Albert J. Arias, MD, MS
Associate Professor, Psychiatry Virginia Commonwealth University School of Medicine. Associate Division Chair, Addiction Psychiatry and Addiction Medicine. Dr. Arias has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

We have five main medications to offer patients with alcohol use disorder: acamprosate, disulfiram, gabapentin, naltrexone (PO or IM), and topiramate. The combination of naltrexone and gabapentin may work better than either of these two medications alone.

Biomarkers of Alcohol Use

October 2, 2019

The newer biomarkers of alcohol use include carbohydrate-deficient transferrin; ethyl glucuronide and ethyl sulfate; and phosphatidylethanol.

N-acetylcysteine Not Effective for Cannabis Use Disorder in Adults

October 2, 2019

Brian Frankel, MD

Brian Frankel, MD Dr. Frankel has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

N-acetylcysteine (NAC), an over-the counter supplement related to the amino acid cysteine, has been shown to have some efficacy in adolescents with cannabis use disorder (CUD). This current study explores whether NAC can be effective for CUD in adult patients as well.

Primer: Confidentiality in Addiction Treatment

August 1, 2019

Addiction is stigmatized, resulting in historically strict confidentiality rules. But how do we interpret HIPAA and other regulations in 2019 addiction practice? Do we need a ROI every time we communicate with other clinicians/institutions, which seems cumbersome and counterproductive? In this article we cover what you need to know about confidentiality in addiction treatment.

Treating Addiction in Patients Transitioning to/from Incarceration

August 1, 2019

Karen Cropsey, PsyD

Karen Cropsey, PsyD

Conatser Turner Endowed Professor of Psychiatry, University of Alabama at Birmingham.

Dr. Cropsey has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Addiction treatment during incarceration is limited, and release from incarceration presents its own set of challenges. In this QA interview, Dr. Karen Cropsey discusses effective treatment options for patients with substance use disorders transitioning to or from incarceration.